Unlocking the full potential of cell therapies for patients around the world
The Future of Cell Therapies
The Future of Cell Therapies
Through the complementary application of biological insights and technological advancements, we aim to unlock the transformative potential of cell therapies.
Our proprietary Cell Squeeze ® technology effectively delivers a variety of therapeutic cargo to cells at scale while preserving cell function, thus opening opportunities to generate new classes of cell therapies across oncology, autoimmune and infectious diseases.
Enrolling Oncology Clinical Trials
Our cell therapies in development seeks to put patients’ immune systems to work against disease. Learn more about our clinical trial targeting HPV16+ solid tumors.
Enhanced Antigen Presenting Cells
SQZ® eAPC Platform
Our SQZ® enhanced APC (eAPC) Phase 1/2 trial (COMMANDER-001) for HPV16+ solid tumors is enrolling in its dose escalation monotherapy phase. Learn more about how this therapeutic candidate uses a patient’s own white blood cells and multiple mRNAs to activate CD8 T cells against disease.
Activating Antigen Carriers
SQZ® AAC Platform
Our SQZ® Activating Antigen Carrier (AAC) Phase 1/2 trial (ENVOY-001) for HPV16+ solid tumors is enrolling in its dose escalation phase. Learn more about how this therapeutic candidate uses a patient's own red blood cells, peptide antigens, and an adjuvant to activate CD8 T cells against disease.
eAPC
AAC
#HOWCELLSWORK Series
We developed the #HowCellsWork education series to support patients, families, and caregivers who want to further understand the therapeutic potential of cell therapies. Explore and enjoy our illustrated series.
Latest News
